Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Monacolin K-rich red yeast rice** is a dietary supplement derived from rice fermented by Monascus species fungi and specifically formulated or selected to have high levels of monacolin K, a compound structurally identical to the pharmaceutical statin drug lovastatin. Its primary indication is the management of high cholesterol (hypercholesterolemia); it inhibits the enzyme HMG-CoA reductase, thus reducing endogenous cholesterol synthesis. Monacolin K-rich red yeast rice may also have effects on blood glucose and cardiovascular risk, though most clinical use centers on lipid-lowering. The supplement may have variable composition, often containing other monacolins and fermentation byproducts such as citrinin, a potential nephrotoxin. U.S. regulatory authorities consider products with high monacolin K content to be unapproved drugs rather than dietary supplements and restrict their sale. The product is used primarily for hypercholesterolemia and is not regulated to pharmaceutical standards, with batch-to-batch variability in monacolin K levels.[1][3][5][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monacolin K-rich red yeast rice.